Stock Scorecard



Stock Summary for Oramed Pharmaceuticals Inc (ORMP) - $2.30 as of 4/25/2024 8:53:44 PM EST

Total Score

16 out of 29

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for ORMP

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ORMP

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ORMP

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for ORMP

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for ORMP

Top 4 Health Care Stocks That May Crash This Quarter - CalciMedica ( NASDAQ:CALC ) , FibroGen ( NASDAQ:FGEN ) 2/2/2024 1:21:00 PM
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer 1/22/2024 10:01:00 PM
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company - Oramed Pharmaceuticals ( NASDAQ:ORMP ) 9/21/2023 10:11:00 PM
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company 9/21/2023 10:11:00 PM
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. - Oramed Pharmaceuticals ( NASDAQ:ORMP ) , Scilex Holding ( NASDAQ:SCLX ) 9/21/2023 8:05:00 PM
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder - Oramed Pharmaceuticals ( NASDAQ:ORMP ) , Scilex Holding ( NASDAQ:SCLX ) 9/13/2023 1:00:00 PM
Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid 8/8/2023 1:50:00 PM
Dow Tumbles 250 Points; CarMax Posts Upbeat Results - CarMax ( NYSE:KMX ) , Greenpro Capital ( NASDAQ:GRNQ ) 6/23/2023 1:51:00 PM
Why Oramed Pharmaceuticals Shares Are Trading Higher Today - Oramed Pharmaceuticals ( NASDAQ:ORMP ) 5/15/2023 3:18:00 PM
Oramed Appoints Ben Shapiro to its Board of Directors 5/1/2023 8:45:00 PM

Financial Details for ORMP

Company Overview

Ticker ORMP
Company Name Oramed Pharmaceuticals Inc
Country USA
Description Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 11/30/2023
Next Earnings Date 5/9/2024

Stock Price History

Last Day Price 2.30
Last Day Price Updated 4/25/2024 8:53:44 PM EST
Last Day Volume 107,258
Average Daily Volume 114,307
52-Week High 5.25
52-Week Low 1.67
Last Price to 52 Week Low 37.72%

Valuation Measures

Trailing PE 16.93
Industry PE 101.20
Sector PE 61.73
5-Year Average PE -6.71
Free Cash Flow Ratio 1.39
Industry Free Cash Flow Ratio 12.66
Sector Free Cash Flow Ratio 30.74
Current Ratio Most Recent Quarter 3.06
Total Cash Per Share 1.65
Book Value Per Share Most Recent Quarter 4.06
Price to Book Ratio 0.62
Industry Price to Book Ratio 5.66
Sector Price to Book Ratio 22.08
Price to Sales Ratio Twelve Trailing Months 76.20
Industry Price to Sales Ratio Twelve Trailing Months 5.48
Sector Price to Sales Ratio Twelve Trailing Months 5.16

Share Statistics

Total Shares Outstanding 40,519,200
Market Capitalization 93,194,160
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 115.11%
Reported EPS 12 Trailing Months 0.14
Reported EPS Past Year 0.21
Reported EPS Prior Year -0.37
Net Income Twelve Trailing Months 5,525,000
Net Income Past Year 5,525,000
Net Income Prior Year -36,561,000
Quarterly Revenue Growth YOY -100.00%
5-Year Revenue Growth -11.36%

Balance Sheet

Total Cash Most Recent Quarter 66,768,000
Total Cash Past Year 66,768,000
Total Cash Prior Year 47,950,000
Net Cash Position Most Recent Quarter 66,443,000
Net Cash Position Past Year 66,443,000
Long Term Debt Past Year 325,000
Long Term Debt Prior Year 25,000
Total Debt Most Recent Quarter 325,000
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 163,821,000
Total Stockholder Equity Prior Year 151,812,000
Total Stockholder Equity Most Recent Quarter 163,821,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.13
MACD Signal -0.09
20-Day Bollinger Lower Band 1.88
20-Day Bollinger Middle Band 2.66
20-Day Bollinger Upper Band 3.44
Beta 1.82
RSI 32.86
50-Day SMA 2.87
200-Day SMA 7.28

System

Modified 4/25/2024 8:14:14 AM EST